Mikhail Konoplyannikov, Svetlana Kotova*, Vladimir Baklaushev, Anatoly Konoplyannikov, Vladimir Kalsin, Peter Timashev and Alexander Troitskiy Pages 3132 - 3142 ( 11 )
Ischemic Heart Disease (IHD) has been recognized as the main cause of mortality in the modern world. Application of cell therapy technologies for the IHD treatment has been actively studied from the beginning of 2000s. The review is dedicated to the use of mesenchymal stem cells (MSC) in the therapy of IHD. The strategies of the MSC modification in vitro for improvement of their regenerative potential are extensively discussed, including preconditioning to enhance the cell survival, boosting their paracrine effect and manipulating their cardiomyogenic differentiation. The optimization of the MSC delivery and opportunities related to the use of biomaterials as cell carriers are also discussed. The results of the most important clinical studies on the MSC-based IHD therapy are presented, including those completed and published in the literature and the ongoing clinical trials registered at clinicaltrials.gov by June 2018.
Ischemic heart disease, mesenchymal stem cells, cell therapy, regenerative medicine, clinical trials, MSC-based IHD.
Federal Research Clinical Center of Specialized Medical Care and Medical Technologies of the FMBA of Russia, Moscow, Federal Research Clinical Center of Specialized Medical Care and Medical Technologies of the FMBA of Russia, Moscow, Federal Research Clinical Center of Specialized Medical Care and Medical Technologies of the FMBA of Russia, Moscow, A. Tsyb Medical Radiological Research Center of the Ministry of Health of Russia, Obninsk, Federal Research Clinical Center of Specialized Medical Care and Medical Technologies of the FMBA of Russia, Moscow, Institute for Regenerative Medicine, Sechenov University, Moscow, Federal Research Clinical Center of Specialized Medical Care and Medical Technologies of the FMBA of Russia, Moscow